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completed by in vitro assays evaluating the intraerythrocytic transfer of sultiame and 
by a pharmacokinetic model assessing its distribution. Single oral doses of sultiame 
(Ospolot®	 50,	 100,	 and	 200	mg)	were	 administered	 in	 open-label	 to	 four	 healthy	
volunteers.	 Serial	 plasma,	whole	 blood,	 and	urine	 samples	were	 collected.	A	 spik-
ing	experiment	was	also	performed	 to	characterize	 sultiame's	exchanges	between	
plasma	and	erythrocytes	in	vitro.	Pharmacokinetic	parameters	were	evaluated	using	
standard	 noncompartmental	 calculations	 and	 nonlinear	 mixed-effect	 modeling.	
The	 plasma	 maximal	 concentrations	 (Cmax)	 showed	 striking	 nonlinear	 disposition	
of	 sultiame,	with	a	10-fold	 increase	while	doses	were	doubled.	Conversely,	whole	









unpublished. The noticeable nonlinearity in sultiame disposition should be taken into 
account for the design of future studies and the interpretation of therapeutic drug 
monitoring results.
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1  | INTRODUC TION
Sultiame	 (Bayer	 1960,	 MW	 290	 g/mol)1	 is	 a	 cyclic	 sulfonamide,	




In	addition,	 an	 inhibitory	action	on	 sodium	channels	possibly	 con-
tributes to its antiepileptic efficacy.2
Sultiame is a first choice treatment in some countries for benign 
childhood	epilepsy	with	centrotemporal	spikes,	a	common	nonlesional	
epilepsy syndrome of childhood usually appearing between 4 and 
12	years	of	age	characterized	by	nocturnal	oro-facial	motor	or	sensory	
seizures,	with	or	without	bilateral	propagation.3 The overall prognosis 
is	good,	with	spontaneous	disappearance	of	epilepsy	at	adolescence.	
However,	some	children	may	have	mild	neurocognitive	deficits	some-
times linked to interictal epileptiform discharges on electroenceph-
alogram.	Although	not	 all	 cases	deserve	 a	 treatment,	 patients	with	
more	 frequent	 seizures	 benefit	 from	 a	 course	 of	 antiseizure	 drug.	
Sultiame has been reported to be well tolerated and possibly more 






have	been	published	 for	 bioavailability	 (F),	 apparent	 volume	of	 dis-
tribution	 (V/F),	 and	apparent	clearance	 (CL/F).	Plasma-free	 fraction	
amounts	to	71%.	Plasma	levels	are	said	to	display	a	significant	degree	
of	 between-	 and	within-individual	 variability,	 even	 at	 steady	 state.	
The	manufacturer	mentions	a	mixed	elimination	by	metabolism	(hy-
droxylation)	and	 renal	excretion,	 the	 latter	concerning	30%-60%	of	





indicated a marked uptake into erythrocytes that we possibly at-
tributed	 to	 sultiame's	 affinity	 for	 CA	 abundant	 in	 erythrocytes.10 
A	 secondary	 aim	 was	 thus	 defined	 to	 characterize	 sultiame's	 ex-
changes between plasma and erythrocytes through an in vitro spik-
ing	experiment.




95	kg	and	a	body	mass	index	of	18-29	kg/m2. Subjects with a history 
or evidence of clinically significant diseases or interfering conditions 
were	 excluded.	 Other	 exclusion	 criteria	 included:	 history	 of	 any	
clinically significant laboratory value including serology for hepatitis 
and	HIV,	relevant	alcohol	or	drug	abuse,	recent	acute	illness,	or	use	
of any medication the week prior to study.
Single	oral	doses	of	50,	100,	and	200	mg	of	sultiame	(Ospolot®,	
immediate-release	 coated	 tablets)	 were	 administered	 in	 fasting	
conditions,	in	open-label,	during	periods	1,	2,	and	3,	respectively,	
at	 4-6	weeks	 interval.	On	 each	 period,	 serial	 plasma	 and	whole	
blood	 samples	were	collected	predose,	 then	at	15,	30	min,	1,	2,	
3,	 4,	 5,	 6,	 8,	 10,	 24,	 48,	 72	 168,	 336,	 and	 504	 hours	 postdose.	
Plasma	and	whole	blood	samples	were	stored	at	−	80°C	until	anal-
ysis.	Hematocrit	was	measured	using	a	microhematocrit	centrifuge	










The	 quantification	 of	 sultiame	 in	whole	 blood,	 plasma,	 and	 urine	
was	 performed	 using	 a	 high-performance	 liquid	 chromatography	
coupled	 to	 tandem	triple	quadrupole	mass	spectrometry	 (LC-MS/
MS)	method	developed	and	validated	purposely	for	the	trial.	Briefly,	
300	µL	of	methanol	 (MeOH)	containing	 the	 internal	 standard	 (IS)	
sultiame-D4	 (Toronto	Research	Chemicals,	Canada)	was	added	 to	

















assay	has	been	applied	 for	 the	 analyses	of	Certified	External	QC	
samples of sultiame in plasma (ClinChek®	N°	14,082	 and	RECIPE	




     |  3 of 9DAO et Al
2.3 | Pharmacokinetic parameters
Erythrocytic	concentrations	(Cery)	were	deduced	from	whole	blood	




computed for each volunteer using standard noncompartmental cal-
culations with Stata®	(version	13,	StataCorp.	2013,	Stata	Statistical	
Software,	College	Station	TX,	USA).
The	 area	 under	 the	 curve	 for	 a	 single	 dose	 (AUC0-inf)	was	 cal-
culated	using	the	log	trapezoidal	rule	with	extrapolation	to	infinity.	




A	 population	 PK	 analysis	 was	 also	 performed	 using	 a	 nonlinear	
mixed-effect	 modeling	 approach	 (NONMEM	 version	 7.4,	 ICON	
Development	 Solutions,	 Hanover	 MD,	 USA).	 Based	 on	 graphical	
exploration	 and	 in	 vitro	 experiments,	 a	 two-compartment	 model	




stants of absorption (ka),	elimination	(ke),	association	with	(kon)	and	
dissociation from (koff)	receptors,	maximal	binding	capacity	(Btot),	ap-
parent	central	volume	of	distribution	(Vc/F),	and	erythrocytes’	vol-
ume	of	distribution	(Very).	Note	that	Very actually encompasses the 
volume	of	 all	 types	of	 cells	 containing	 receptors,	 assumed	 to	 tally	
with	the	sampled	erythrocytes.	Plasma	protein	binding	was	assumed	
constant over the whole range of observed concentrations. Renal 
extraction	fraction	(Qren)	was	added	to	characterize	urine	excretion	
with	an	additional	compartment	for	urine	data.	Values	of	kon and koff 
characterized	in	vitro	at	different	temperatures	were	used	as	initial	








and adjustment are available in Supplemental material.
A	 stepwise	 procedure	was	 used	 to	 identify	 the	model	 that	 best	
fitted	the	data,	comparing	two-,	three-,	and	four-compartmental	mod-
els (peripheral or separate intracellular compartments for free and 
bound	 sultiame),	 and	 other	 nonlinear	 models	 (Bmax	 sigmoid	 model).	
Exponential	errors	were	used	for	the	description	of	between-subject	
variability	(BSV)	of	PK	parameters.	Proportional,	additive,	and	mixed	
error models were compared to describe the residual variability. The 




All	 adverse	events	were	 recorded	with	an	evaluation	of	 their	 se-
verity	and	imputability	to	the	study	drug.	Each	volunteer	received	








F I G U R E  1  Compartmental	model	accounting	for	nonlinearity	of	distribution.	Aa,	amount	of	sultiame	at	the	absorption	site;	Ap,	amount	
of	sultiame	in	plasma	and	central	compartment;	Vc,	central	volume	of	distribution;	Aery,	amount	of	sultiame	in	the	cells,	assumed	to	be	bound	
to	receptors;	Very,	cellular	volume	of	distribution;	ka,	absorption	rate	constant;	ke,	elimination	rate	constant;	kon,	constant	of	association	onto	
receptors binding sites; koff,	constant	of	dissociation	from	the	binding	site;	Bbound,	amount	of	occupied	receptors,	assumed	equal	to	Aery;	Bfree,	
amount	of	free	binding	sites;	Btot,	sultiame	maximal	binding	capacity	(mg);	Qren,	renal	fraction	of	the	elimination	rate;	Foral,	oral	bioavailability,	
assumed	equal	to	1




predrug	 (0	hour)	 at	0.5,	1,	2,	4,	6,	8,	10,	 and	24	hours	postdose.	
Vital	 signs	 (supine	blood	pressure,	 heart	 rate,	 body	 temperature,	
and	respiratory	frequency)	were	measured	predose	and	at	1,	2,	4,	6,	
8,	10,	and	24	hours	postdose.	Laboratory	parameters,	drug	screen,	
and urinalysis were performed at screening and at study end.
2.5 | In vitro assays
A	spiking	experiment	was	performed	to	better	characterize	sultiame	











antiepileptic	 agents	 known	 for	 their	 affinity	 for	 CA	 (zonisamide	
and	 topiramate),	 added	 at	 equimolar	 concentration	 to	 20	 mg/L	
of	 sultiame.	 Similar	 ranges	of	 inhibition	 constants	 for	CA	 II	were	
reported in the literature for these three substances.13 Samples 
F I G U R E  2  Log-transformed	plasma	
and erythrocyte concentrations of 
sultiame:	predicted	concentration-time	
profiles	(continuous	lines)	and	geometric	
mean and standard errors of observations 
in	erythrocytes	(A)	and	plasma	(B),	after	
administration of single doses of 50 mg 
(circles),	100	mg	(diamonds),	and	200	mg	
(triangles).	Insets	zoom	on	the	first	
24 hours after drug intake
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(1	mL)	were	drawn	before	and	at	2,	4,	6,	8,	10,	15,	20,	30,	45,	60,	
and	120	min	after	addition	of	the	competitor.	Sultiame,	zonisamide,	
and	 topiramate	 concentrations	 were	 then	 analyzed.	 All	 samples	





quantified	 with	 the	 previously	 described	 HPLC-MS/MS	 method,	
using	matrix-matched	calibration	and	quality	controls.	The	sultiame	
concentrations determined in erythrocytes were corrected for the 





out.	Age	 (mean	±	SD)	was	25	±	3	 years	 (range	22-28	years)	 and	
weight	69	±	2	kg	 (range	65-71	kg)	at	 inclusion.	Safety	and	toler-
ability assessments revealed limited impact on gastrointestinal 
and	central	nervous	system	tolerance	using	VAS.	Fatigue	was	the	
symptom	most	frequently	reported.	Transient	facial	and	limb	par-
esthesia were reported by three subjects after intake of the high-




Average	 sultiame	 plasma	 and	 whole	 blood	 concentrations	 after	
single	oral	doses	of	50,	100,	and	200	mg,	administered	at	4	weeks	
intervals,	are	represented	in	Figure	2.	The	plasma	maximal	concen-
tration (Cmax)	 revealed	 striking	 nonlinear	 disposition	 of	 sultiame,	
with	10-fold	increases	between	each	dose	levels,	while	doses	only	
doubled.	Conversely,	whole	 blood	Cmax increased less than dose 
proportionally	and	were	much	higher	than	those	in	plasma.	PK	pa-
rameters of sultiame obtained by noncompartmental calculations 
are	reported	 in	Table	1	 for	each	dose.	Nonlinearity	 for	CL/F	and	
area	under	the	curve	(AUC0-inf)	is	salient	between	dose	levels,	sug-
gesting	 a	 saturation	process	 in	 distribution	 in	 erythrocytes.	 Low	










A	 2-compartment	model	 incorporating	 a	 saturable	 ligand	 to	 re-
ceptor	binding,	completed	with	the	in	vitro	kon and koff values and 
a	compartment	for	urines,	best	described	the	data.	In	addition	to	
CL/F	(ΔOFV	of	−	74),	BSV	on	QRen (ΔOFV	−	21)	was	incorporated	




assuming a saturable amount of binding sites in erythrocytes and 
possibly other types of cells. There were no indications for using 
more	complicated	models:	for	example,	a	sigmoid	Bmax model did 
not perform better (ΔAIC	+	29);	adding	a	linear	component	to	ac-
count for nonsaturable transfer of sultiame into erythrocytes did 
not provide strong evidence of model improvement (ΔAIC	−	2.5).	
Conversely,	 classical	 linear	models	were	 unable	 to	 describe	 the	
data. The final base population parameters are listed in Table 2 
and the average concentration predictions for each dose level are 
shown	on	Figure	2.	Individual	profiles	of	predicted	concentrations	
TA B L E  1  Noncompartmental	pharmacokinetic	parameters
 
Sultiame 















t1/2	(h) 50.8	(62) 90.9	(19) 40	(31)
CL/F	(L/h) 40.4	(93) 11.7	(25) 8.3	(26)
V/F	(L) 2964	(21) 1529	(21) 480	(26)
Whole blood parameters







t1/2	(h) 313	(23) 233	(16) 253	(21)
CL/F	(L/h) 0.015	(37) 0.008	(34) 0.044	(41)

















taken up almost instantaneously into the erythrocytes and the eryth-
rocyte/plasma ratio reached a steady state after about 10 minutes. 
This erythrocyte/plasma ratio decreased from 800 at concentrations 
of	10	mg/L	or	less,	to	less	than	30	for	concentrations	of	20	mg/L	and	
above. These results indicate that the saturation of erythrocytes oc-
curs	around	or	slightly	above	20	mg/L	(of	whole	blood	concentration).	
At	higher	concentrations,	the	excess	of	sultiame	increasingly	distributes	
between	 the	plasma	and	 the	erythrocytes	 (Figure	4).	Decreasing	 the	
experiment	temperature	slowed	down	the	rate	of	entry	of	sultiame	into	
the	cells,	without	significantly	modifying	the	erythrocyte/plasma	ratios.	












erythrocytes,	with	 an	 erythrocyte/plasma	 ratio	 close	 to	1,	 not	 influ-
enced	by	the	addition	of	sultiame	(data	not	shown).
4  | DISCUSSION
To	our	 knowledge,	our	preliminary	 clinical	PK	 study	 is	 the	 first	 to	
provide	a	detailed	description	of	sultiame's	PK	characteristics,	since	





ratio	 further	 confirms	 sultiame's	 strong	 affinity	 for	 erythrocytes.	
The noticeable decrease in this ratio along escalating dosages indi-







tion rate constant (kD)	of	4.5	µM	could	be	estimated	in	vitro.
15,16	A	value	
comparable to the estimated kD of our final model (koff/kon	=	4	µM).	
Competition studies indicated that sultiame had a stronger affinity for 
erythrocytes	 than	 zonisamide.	Clinically,	 this	 suggests	 that	 displace-




ratio might also be associated with variations in efficacy when sultiame 
is	given	as	an	add-on	antiepileptic	drug	in	clinical	practice.
Using	 noncompartmental	 approaches,	 plasma	 and	 especially	
whole blood t1/2 appeared to be markedly longer than previously 
reported.6-8	 The	 range	 2-16	 hours	 currently	 reported	 in	 the	man-
ufacturer's	 information	 might	 have	 resulted	 from	 difficulties	 to	
TA B L E  2  Final	population	compartmental	model	parameters
Parameter
Population pharmacokinetics analysis Bootstrap evaluation
Estimate RSE(%) BSV(%) RSE (%) Median CI95% BSV(%) CI95%
CLplasma	(L/h) 9.95 11.8 28.8 15 9.95 (8.4;11.8) 27 (0.5;42)
Vc	(L) 64.8 18.1 – – 64.8 (52.1;80.6) – –
Very	(L) 3.27 7 – – 3.27 (2.8;3.6) – –
ka (h
−1) 1.88 13.8 – – 1.88 (1.3;2.1) – –
kon (h
−1·µM−1) 2018 – – – 2018 – – –
koff (h
−1) 8080 19.2 – – 8080 (6626;11209) – –
Btot	(mg) 111 2.1 – – 111 (105;117) – –
QRen	(%) 28.8 13 24.3 67.6 28.8 (22.9;37.4) 24 (0.8;33)
σprop,c	(CV%) 0.426 9 – – 0.424 (0.38;0.45) – –
σprop,ery	(CV%) 0.3 11 – – 0.299 (0.21;0.32) – –
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determine low sultiame concentrations with analytical methods 
available	in	the	past.	Considering	whole	blood,	we	observed	t1/2 val-
ues	of	up	 to	13	days.	As	 the	 terminal	plasma	 t1/2 is dependent of 
erythrocytes affinity for sultiame and limited by its dissociation from 
its	binding	site	in	erythrocytes,	our	compartmental	model	predicts	
that plasma concentration curves should display a terminal t1/2 not 
different	 from	whole	 blood.	 However,	 plasma	 concentrations	 fol-




terminal phase of plasma concentrations after treatment interrup-
tion. Still an important accumulation of sultiame during long term is 
not	expected	despite	this	presumably	long	t1/2,	due	to	the	saturable	
aspect	of	the	uptake	by	the	receptor-rich	intracellular	compartment.
The distribution volume corresponding to whole blood ranges 




partmental	V/F	 and	CL/F	 estimates	 reveal	 as	well	 a	 striking	 dose	
dependency,	 consistent	with	 the	saturable	aspect	of	 sultiame	dis-
tribution. Our compartmental model does not indicate that sultiame 
CL/F	 from	 the	 central	 plasma	 compartment	would	have	 any	non-
linear	aspect.	 In	 terms	of	urinary	excretion,	a	constant	renal	CL/F	
(range:	0.13-0.17	L/h)	 is	 actually	observed,	 despite	 the	nonlinear-
ity	 in	 urinary	 recovery	 of	 unchanged	 sultiame,	 again	 consequent	
to saturable intracellular uptake. The fraction eliminated by renal 
route	 is	 28.8%,	 as	 already	 described	 in	 the	 summary	 of	 product	
characteristics.8
F I G U R E  3   Concentrations of sultiame 
in	plasma	(A)	and	in	erythrocytes	(B)	

























vivo for doses of 100 mg and above (see concentrations in eryth-




fitted our data better than the nonlinear disposition models found in 
the	literature	that	used	a	sigmoid	Bmax	equation	to	account	for	non-
linearity.11,18	A	ligand	to	receptor	model,	where	the	ratio	of	kon/koff 
F I G U R E  4   In vitro concentrations of 




represent the spiked concentration of 
sultiame with the corresponding plasma 
and erythrocyte concentrations
F I G U R E  5   In	vitro	concentrations	of	sultiame	in	erythrocytes	and	plasma	at	different	temperatures,	values	of	concentrations	at,	
respectively,	4°C,	21°C,	and	37°C	are	represented	along	incubation	time	(with	a	concentration	of	20	mg/L).	Observed	erythrocyte	
concentrations	(open	circles),	observed	plasma	concentrations	(black	circles),	and	predicted	concentration	profiles	(continuous	lines)	are	
represented.	Estimates	of	kon and koff for each temperature derived from the model are represented in the table below
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ticularly in the pediatric population as part of therapy of benign child-
hood epilepsy with centrotemporal spikes.3 They should also be taken 
into	consideration	to	elaborate	an	adequate	framework	of	interpreta-
tion for the therapeutic monitoring of sultiame circulating concentra-
tions,	not	only	in	plasma	but	also	in	whole	blood,	which	might	present	
a clinical interest as for other recent antiepileptic agents.19
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